Asia Pacific Clinical Trials Market Forecast to 2028 - Regional Analysis - by Study Design, Phase, and Indication

The Asia Pacific clinical trials market is expected to grow from US$ 8,670.68 million in 2022 to US$ 13,114.04 million by 2028. It is estimated to grow at a CAGR of 7.1% from 2022 to 2028.

AI-Driven Clinical Trials Fuels Asia Pacific Clinical Trials Market

Adoption of Artificial Intelligence (AI) offers innovative ways to collect and manage clinical trial data and reduces dependency on manual operations. Thus, AI acts as a game changer for life science companies involved in the drug development process.

The Oncology Data Science team at AstraZeneca feeds these data into a system that utilizes AI and other statistical tools to generate novel hypotheses for oncology drug development. To transform the process of oncology data feed, the team is adopting complex datasets for accessibility, interoperability, and reusability of data as per "GOFAIR (Findability, Accessibility, Interoperability, and Reuse of digital assets)" - the set of principles. Such integration empowers data collection from specific clinical trials and projects to be accessible across the company's drug development teams in compliance with data protection laws.

AstraZeneca is collaborated with companies such as Tempus to leverage real-world data and represent patients globally. Such strategic partnerships are anticipated to offer crucial evidence about patient outcomes without revealing the identification of the clinical trial participants in the datasets.

Asia Pacific Clinical Trials Market Overview

Asia Pacific (APAC) is the fastest-growing regional market for global clinical trials and is segmented into China, Japan, India, South Korea, Australia, Indonesia, Thailand, Vietnam, and the Rest of Asia Pacific. Countries such as Australia, India, and South Korea are estimated to witness various growth opportunities due to the rising development in the healthcare sector. In addition, governments of these countries are increasing their efforts to provide clinical trials. Also, rise in the incidence of chronic diseases and growing awareness regarding clinical trials are likely to offer greater growth opportunities to the market players in the coming years.

Asi

a Pacific clinical trials market Revenue and Forecast to 2028 (US$ Million)

Asia Pacific Clinical Trials Market Segmentation

The Asia Pacific clinical trials market is segmented into phase, study design, indication, and country.

Based on phase, the Asia Pacific clinical trials market is segmented into phase I, phase II, phase III, and phase IV. The phase III segment registered the largest Asia Pacific clinical trials market share in 2022.

Based on study design, the Asia Pacific clinical trials market is segmented into interventional, observational, and expanded access. The interventional segment held the largest Asia Pacific clinical trials market share in 2022.

Based on indication, the Asia Pacific clinical trials market is segmented into autoimmune/inflammation, pain management, oncology, CNS condition, diabetes, obesity, cardiovascular, and others. The oncology segment held the largest Asia Pacific clinical trials market share in 2022.

Based on country, the Asia Pacific clinical trials market has been categorized into China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. China dominated the Asia Pacific clinical trials market in 2022.

Charles River Laboratories International Inc, ICON Plc, IQVIA Holdings Inc, Laboratory Corp of America Holdings, Parexel International Corp, SGS SA, SIRO Clinpharm Pvt Ltd, Syneos Health Inc, Thermo Fisher Scientific Inc, and WuXi AppTec Co Ltd. are some of the leading companies operating in the Asia Pacific clinical trials market.

Reasons to Buy

• Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Asia Pacific clinical trials market.
• Highlights key business priorities in order to assist companies to realign their business strategies
• The key findings and recommendations highlight crucial progressive industry trends in the Asia Pacific clinical trials market, thereby allowing players across the value chain to develop effective long-term strategies
• Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
• Scrutinize in-depth Asia Pacific market trends and outlook coupled with the factors driving the clinical trials market, as well as those hindering it
• Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution